IS7324A - Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka - Google Patents

Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka

Info

Publication number
IS7324A
IS7324A IS7324A IS7324A IS7324A IS 7324 A IS7324 A IS 7324A IS 7324 A IS7324 A IS 7324A IS 7324 A IS7324 A IS 7324A IS 7324 A IS7324 A IS 7324A
Authority
IS
Iceland
Prior art keywords
analogues
synchronous
hormone receptor
receptor activity
nuclear hormone
Prior art date
Application number
IS7324A
Other languages
English (en)
Inventor
E. Salvati Mark
Aaron Balog James
A. Pickering Darcia
Giese Sören
Fura Aberra
Li Wenying
N. Patel Ramesh
L. Hanson Ronald
Mitt Toomas
Y. Roberge Jacques
R. Corte James
H. Spergel Steven
A. Rampulla Richard
N. Misra Raj
Hai-Yun
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7324A publication Critical patent/IS7324A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7324A 2001-12-19 2004-06-18 Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka IS7324A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2511601A 2001-12-19 2001-12-19
PCT/US2002/040598 WO2003062241A1 (en) 2001-12-19 2002-12-18 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (1)

Publication Number Publication Date
IS7324A true IS7324A (is) 2004-06-18

Family

ID=27609007

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7324A IS7324A (is) 2001-12-19 2004-06-18 Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka

Country Status (31)

Country Link
EP (1) EP1458723B1 (is)
JP (1) JP2005523257A (is)
KR (1) KR20040086248A (is)
CN (1) CN1589271A (is)
AR (1) AR037950A1 (is)
AT (1) ATE411319T1 (is)
AU (1) AU2002361785B2 (is)
BR (1) BR0215281A (is)
CA (1) CA2471342A1 (is)
CO (1) CO5640082A2 (is)
DE (1) DE60229435D1 (is)
DK (1) DK1458723T3 (is)
ES (1) ES2314127T3 (is)
GE (1) GEP20063817B (is)
HR (1) HRP20040567A2 (is)
HU (1) HUP0402554A3 (is)
IL (1) IL162547A0 (is)
IS (1) IS7324A (is)
MX (1) MXPA04005876A (is)
NO (1) NO20043068L (is)
NZ (1) NZ533471A (is)
PL (1) PL370904A1 (is)
PT (1) PT1458723E (is)
RU (1) RU2330038C2 (is)
SI (1) SI1458723T1 (is)
TW (1) TWI263640B (is)
UA (1) UA78265C2 (is)
UY (1) UY27595A1 (is)
WO (1) WO2003062241A1 (is)
YU (1) YU53604A (is)
ZA (1) ZA200404812B (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1467979B1 (en) 2001-12-19 2008-08-13 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function
US7202264B2 (en) 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
FR2860793A1 (fr) * 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
WO2005049621A1 (en) * 2003-11-13 2005-06-02 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
WO2005090300A1 (en) * 2004-03-17 2005-09-29 Pfizer Products Inc. Novel benzyl(idene)-lactam derivatives
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
CA2760387A1 (en) * 2009-04-30 2010-11-04 Sumitomo Chemical Company, Limited Thiophene derivative
CN102482228A (zh) 2009-07-17 2012-05-30 盐野义制药株式会社 含有内酰胺或苯磺酰胺化合物的药物
JP2013504531A (ja) 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
MA33904B1 (fr) 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
JP6156074B2 (ja) * 2013-11-08 2017-07-05 住友化学株式会社 スクシンイミド化合物及びその用途
PE20161372A1 (es) 2014-02-03 2017-01-08 Vitae Pharmaceuticals Inc Inhibidores de dihidropirrolopiridina de ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
UA123201C2 (uk) * 2014-12-19 2021-03-03 Араґон Фармасьютікалз, Інк. Спосіб отримання сполуки діарилтіогідрантоїну
KR102110566B1 (ko) * 2015-01-20 2020-05-13 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
JP6914257B2 (ja) 2015-11-20 2021-08-04 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのモジュレーター
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN110114349B (zh) 2016-12-29 2022-03-15 埃尼奥制药公司 作为抗病毒剂的噻吩衍生物
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
US12552806B2 (en) 2020-03-20 2026-02-17 University Of Southern California Androgen receptor regulation by small molecule enantiomers
EP4121044A4 (en) * 2020-03-20 2024-03-13 University Of Southern California ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS
TW202208356A (zh) 2020-05-08 2022-03-01 美商哈利亞製藥公司 Ｎｅｋ７激酶抑制劑
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
US20250064948A1 (en) * 2022-02-14 2025-02-27 The Johns Hopkins University Gcpii inhibition for the treatment of sarcopenia and aging
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) * 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
JPS63170383A (ja) * 1987-02-26 1988-07-14 Nippon Zeon Co Ltd 脂環式ジカルボン酸イミド化合物
CA2069318A1 (en) * 1989-10-27 1991-04-28 Engelbert Ciganek (n-phthalimidoalkyl) piperidines
DE69729213T2 (de) * 1996-10-25 2005-05-04 Daiichi Pharmaceutical Co., Ltd. Tricyclische aminderivate
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2356162A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Substituted tricyclics
US6521753B1 (en) * 2000-05-31 2003-02-18 Johnson & Johnson Vision Care, Inc. Indolinospiropyran compounds and methods for their manufacture
CZ20024214A3 (cs) * 2000-06-28 2003-04-16 Bristol-Myers Squibb Company Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití
EP1319007B9 (en) * 2000-09-19 2007-10-10 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Also Published As

Publication number Publication date
PL370904A1 (en) 2005-05-30
DK1458723T3 (da) 2009-02-09
MXPA04005876A (es) 2005-05-16
EP1458723A1 (en) 2004-09-22
EP1458723B1 (en) 2008-10-15
RU2330038C2 (ru) 2008-07-27
KR20040086248A (ko) 2004-10-08
NO20043068L (no) 2004-09-08
UY27595A1 (es) 2003-07-31
WO2003062241A8 (en) 2004-10-21
CN1589271A (zh) 2005-03-02
DE60229435D1 (de) 2008-11-27
HUP0402554A2 (hu) 2005-03-29
HUP0402554A3 (en) 2009-01-28
CA2471342A1 (en) 2003-07-31
PT1458723E (pt) 2008-12-26
CO5640082A2 (es) 2006-05-31
GEP20063817B (en) 2006-05-10
SI1458723T1 (sl) 2009-02-28
RU2004122403A (ru) 2005-05-27
AR037950A1 (es) 2004-12-22
BR0215281A (pt) 2004-10-19
ZA200404812B (en) 2005-08-26
HRP20040567A2 (en) 2005-06-30
YU53604A (sh) 2006-08-17
UA78265C2 (en) 2007-03-15
TWI263640B (en) 2006-10-11
ATE411319T1 (de) 2008-10-15
JP2005523257A (ja) 2005-08-04
AU2002361785B2 (en) 2008-05-22
ES2314127T3 (es) 2009-03-16
IL162547A0 (en) 2005-11-20
NZ533471A (en) 2007-05-31
WO2003062241A1 (en) 2003-07-31
TW200304810A (en) 2003-10-16
EP1458723A4 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
IS7324A (is) Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
NO20031266L (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
DK1208095T3 (da) Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
ATE305920T1 (de) Bradykinin receptorantagoniste
DK1237559T3 (da) Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran
ATE272632T1 (de) Muskarin-rezeptor antagonisten
EE200200204A (et) Asendatud bensimidasooli preparaat
NO20016053L (no) IL-8 reseptor-antagonister
DK1351683T3 (da) Kombination indeholdende en AT-receptorantagonist og en insulinsekretionsforstærker eller en insulinsensibilisator
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO20016052L (no) IL-8-reseptor-antagonister
DK1292697T3 (da) Fremgangsmåde til fremstiling af fysiologisk aktivt IL-18-polypeptid
DE60033145D1 (de) Il-8 rezeptorantagonist
ATE277043T1 (de) Vitronectin rezeptor antagonist
ATE264301T1 (de) Muscarin-antagonisten
NO20015662D0 (no) Oralt aktive A1-adenosinreseptorantagonister
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20015774L (no) IL-8 reseptorantagonister
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
NO20032415D0 (no) Forbindelser som er aktive på glukokortikoidreseptor II
NO20041291D0 (no) Medisinske preparater som inneholder angiotensin II-reseptorantagonist
NO20021475D0 (no) Vasopressinantagonist, formulering og fremgangsmåte
NO20016102D0 (no) IL-8 reseptorantagonister